Aelis Farma Management
Management criteria checks 2/4
Aelis Farma's CEO is Pier Piazza, appointed in Jan 2022, has a tenure of 2.92 years. total yearly compensation is €473.61K, comprised of 63.3% salary and 36.7% bonuses, including company stock and options. directly owns 17.87% of the company’s shares, worth €5.06M. The average tenure of the management team and the board of directors is 2.9 years and 2.9 years respectively.
Key information
Pier Piazza
Chief executive officer
€473.6k
Total compensation
| CEO salary percentage | 63.3% |
| CEO tenure | 2.9yrs |
| CEO ownership | 17.9% |
| Management average tenure | 2.9yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Aelis Farma SA (EPA:AELIS) Might Not Be As Mispriced As It Looks After Plunging 26%
Dec 13
Take Care Before Jumping Onto Aelis Farma SA (EPA:AELIS) Even Though It's 29% Cheaper
Oct 21Aelis Farma SA's (EPA:AELIS) 49% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 06Some Confidence Is Lacking In Aelis Farma SA (EPA:AELIS) As Shares Slide 49%
Sep 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€7m |
| Mar 31 2024 | n/a | n/a | -€6m |
| Dec 31 2023 | €474k | €300k | -€5m |
| Sep 30 2023 | n/a | n/a | -€5m |
| Jun 30 2023 | n/a | n/a | -€6m |
| Mar 31 2023 | n/a | n/a | -€10m |
| Dec 31 2022 | €594k | €296k | -€14m |
| Sep 30 2022 | n/a | n/a | -€14m |
| Jun 30 2022 | n/a | n/a | -€14m |
| Mar 31 2022 | n/a | n/a | -€6m |
| Dec 31 2021 | €501k | €239k | €574k |
| Sep 30 2021 | n/a | n/a | €2m |
| Jun 30 2021 | n/a | n/a | €3m |
| Mar 31 2021 | n/a | n/a | €504k |
| Dec 31 2020 | €347k | €210k | -€2m |
Compensation vs Market: Pier's total compensation ($USD492.22K) is above average for companies of similar size in the French market ($USD311.92K).
Compensation vs Earnings: Pier's compensation has been consistent with company performance over the past year.
CEO
Pier Piazza (63 yo)
2.9yrs
Tenure
€473,614
Compensation
Dr. Pier Vincenzo Piazza, MD, Ph D., is CEO of Aelis Farma S.A. from January 11, 2022 and serves as its Director since 2017. Dr. Piazza is an entrepreneur and renowned scientist who has been involved in es...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.9yrs | €473.61k | 17.87% € 5.1m | |
| Head of Finance | 2.9yrs | no data | no data | |
| Chief Operating Officer | no data | no data | no data | |
| Head of Legal | 2.9yrs | no data | no data | |
| Chief Corporate Development Officer | less than a year | no data | no data | |
| Head of Discovery & IP Leader | 2.9yrs | no data | no data | |
| Head of Preclinical Development | 2.9yrs | no data | no data | |
| Head of Clinical Development | 2.9yrs | no data | no data | |
| Head of Pharmaceutical Development | 2.9yrs | no data | no data |
2.9yrs
Average Tenure
Experienced Management: AELIS's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.9yrs | €473.61k | 17.87% € 5.1m | |
| Censor | 2.9yrs | €30.00k | 11.78% € 3.3m | |
| Independent Chairman of the Board | 4.8yrs | €100.00k | no data | |
| Chairman of the Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.9yrs | no data | no data | |
| Independent Director | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 3.9yrs | no data | 8.63% € 2.4m | |
| Independent Director | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.9yrs
Average Tenure
64yo
Average Age
Experienced Board: AELIS's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 21:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aelis Farma SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dylan van Haaften | Bryan Garnier & Co |
| David Seynnaeve | Degroof Petercam |
| Martial Descoutures | ODDO BHF Corporate & Markets |